louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01673191: A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus
Official title: A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Macular Edema
Diabetes Mellitus
Lead sponsor: Retinal Consultants of Arizona
Sponsor class: OTHER
Collaborators: name: Allergan
First posted: 2012-08-27
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: There is a need to find an effective therapy for diabetic patients who develop macular edema after cataract surgery.

Detailed description: The objective of this study is to assess the safety and efficacy of the OZURDEX® intraocular implant in patients with diabetes mellitus, who develop macular edema after cataract surgery

Eligibility criteria: Inclusion Criteria:

* Patient has diagnosis of Diabetes Mellitus, Type I or II.
* Patient has experienced the development of macular edema following cataract surgery in at least one eye.
* Patient has had cataract surgery within 90 days prior to the screening visit.

Exclusion Criteria:

* Patient has other significant ocular disease in study eye, including glaucoma.
* Patient has any active infection in the study eye.
* Patient has uncontrolled systemic illness (i.e., uncontrolled blood pressure, uncontrolled diabetes mellitus).
* Patient has experienced a significant increase in intraocular pressure following a prior treatment with topical or intravitreal steroidal medication.
* Patient has received the OZURDEX® implant before in the study eye.

Primary outcomes:
measure: Mean Change in Best Corrected Visual Acuity
timeFrame: 1 months
measure: Mean Change in Best Corrected Visual Acuity
timeFrame: 2 months
measure: Mean Change in Best Corrected Visual Acuity
timeFrame: 3 months
measure: Mean Change in Central Retinal Thickness
timeFrame: 1 month
measure: Mean Change in Central Retinal Thickness
timeFrame: 2 months
measure: Mean Change in Central Retinal Thickness
timeFrame: 3 months
measure: Mean Change in Intraocular Pressure
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Phoenix
country: United States
facility: Retinal Consultants of Arizona
state: Arizona
Study officials:
affiliation: Retinal Consultants of Arizona
name: Pravin U Dugel, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00864591: Stress Adenosine Cardiac Magnetic Resonance (MR) Comparison With Single Photon Emission Computed Tomography (SPECT) Imaging
Official title: Stress Adenosine Cardiac MR Comparison With SPECT Imaging
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Coronary Artery Disease
Cardiac Perfusion
Keywords: SPECT Imaging
Stress adenosine CMR
Lead sponsor: Sheba Medical Center
Sponsor class: OTHER_GOV
First posted: 2009-03-18
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients undergoing SPECT stress imaging, for the evaluation of myocardial ischemia.

The study group will include patients with either normal undergoing SPECT stress imaging or with mild to severe ischemia, to include the entire spectrum of coronary artery disease.

Patients will be pre selected and evaluated by a non-dependent cardiologist in order to verify that patients in whom the repeat stress might pose a serious risk will be excluded from the study.

Brief summary: This study is designed to determine the diagnostic value of adenosine cardiac magnetic resonance (CMR) when compared with SPECT.

The investigators hypothesized that adenosine CMR could detect ischemia and is not inferior to SPECT imaging. In addition stress adenosine cardiac MRI offers a "one stop shop" enabling evaluation of cardiac function, rest and stress perfusion and viability.


Eligibility criteria: Inclusion Criteria:

* Suspected ischemia referred to SPECT stress imaging

Exclusion Criteria:

* Standard contraindications to MRI including (pacemaker/defibrillator, metallic clips on brain aneurysms, metal fragment in the eye, etc...)
* Congestive heart failure.
* Hemodynamic instability.
* History of asthma or bronchospastic disease.
* Arrhythmia
* Creatinine \>1.4
* Non compliant patient, not able to lie supine in the MRI scanner for 1 hour.
* Pregnant patients
* Patients for whom the repeat stress might pose a significant risk.

Primary outcomes:
measure: Stress adenosine cardiac MRIis not inferior to SPECT imaging in diagnosing myocardial ischemia
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Tel hashomer
country: Israel
facility: Chaim Sheba Medical Center
Study officials:
References:
Clinical trial NCT03654391: Study of Obesity Control by Astragalus and Notoginseng Extrats
Official title: Study of Obesity Control by Astragalus and Notoginseng Extrats
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Keywords: Astragalus and Notoginseng extrats
Body weight
BMI
Triglyceride
obese
Lead sponsor: Chung Shan Medical University
Sponsor class: OTHER
First posted: 2018-08-31
Enrollment: 38
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: The effects of the Astragalus and Notoginseng extrats on obesity control was demonstrated in a randomized double-blind, and crossover human trial.

Detailed description: Obesity refers to the body due to physiological or biochemical function of the change caused by excessive accumulation of body fat, resulting in weight gain. Hence, the aim of this study was to evaluate the effects of the Astragalus and Notoginseng extrats on obesity control by a randomized double-blind and crossover human trial. Subjects with simple obesity (body mass index (BMI) ≥ 27 or body fat ≥ 30%) ingested 5 extrats (n = 19) capsules or placebo (n = 19) perday for 12 weeks of a stage. Anthropometric measurements (body weight, body fat, blood pressure) and blood biochemical markers including fasting blood glucose (FBG), albumin, total cholesterol (TC), triglyceride (TG), HDL-C, LDL-C, creatinine (Cr), blood urea nitrogen (BUN), AST, ALT were examined every six weeks.

Eligibility criteria: Inclusion Criteria:

* Body mass index (BMI) ≥ 27 or body fat ≥ 30%;
* No history of serious diseases associated with heart, liver, kidney, endocrine systems or other organs;
* No drugs consumption.

Exclusion Criteria:

* BMI \>35;
* Alcoholic;
* US-controlled diabetics;
* Stoke in past one year;
* High blood pressure;
* Mental diseases or melancholia;
* Pregency or breast-feeding a child.

Primary outcomes:
measure: The changes of body weight and BMI of the subjects.
timeFrame: 12 weeks
Secondary outcomes:
measure: The changes of triglyceride (TG) of the subjects
timeFrame: 12 weeks
Other outcomes:
Locations:
Study officials:
affiliation: Chung Shan Medical University
name: irb@csh.org.tw Mr Shen, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Chang W.L. et al. The inhibitory effect of ginse¬noside Rg1 on glucose and lipid production in human HepG2 cells. Adaptive Medicine. 2013, 5(4), 181-188.
citation: Chang TC, Huang SF, Yang TC, Chan FN, Lin HC, Chang WL. Effect of ginsenosides on glucose uptake in human Caco-2 cells is mediated through altered Na+/glucose cotransporter 1 expression. J Agric Food Chem. 2007 Mar 7;55(5):1993-8. doi: 10.1021/jf062714k. Epub 2007 Feb 2.
citation: Wang CW, Su SC, Huang SF, Huang YC, Chan FN, Kuo YH, Hung MW, Lin HC, Chang WL, Chang TC. An Essential Role of cAMP Response Element Binding Protein in Ginsenoside Rg1-Mediated Inhibition of Na+/Glucose Cotransporter 1 Gene Expression. Mol Pharmacol. 2015 Dec;88(6):1072-83. doi: 10.1124/mol.114.097352. Epub 2015 Oct 1.
Clinical trial NCT00180791: High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood
Official title: Treatment Protocol for High-Risk PNET Brain Tumors in Children With Surgery, Sequential Chemotherapy, Conventional and High-Dose With Peripheral Blood Stem Cell Transplantation and Radiation Therapy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Medulloblastoma
Brain Tumors
Neuroectodermal Tumors, Primitive
Keywords: Brain PNET
Lead sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Sponsor class: OTHER
First posted: 2005-09-16
Enrollment: 71
Sex: ALL
Maximum age (years): 10
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the efficacy of the combination of surgery, conventional chemotherapy, sequential high-dose chemotherapy with peripheral blood stem cell transplantation and reduced dose radiation therapy in high-risk PNET brain tumors.


Eligibility criteria: Inclusion Criteria:

* Medulloblastoma in patients less than 5 years of age
* Brain PNET in patients less than 10 years of age
* Histologically documented diagnosis
* Body weight of \> 8 kg

Exclusion Criteria:

* Parents' refusal

Primary outcomes:
measure: Response of medulloblastoma metastases to the chemotherapy regimen in children less than 5 years of age
measure: Progression-free survival of children less than 10 years of age with brain PNET
Secondary outcomes:
measure: Progression-free survival of children less than 5 years of age with metastatic medulloblastoma
measure: Toxicity
measure: Long term sequelae
Other outcomes:
Locations:
city: Villejuif
country: France
facility: Institut Gustave Roussy
Study officials:
affiliation: Gustave Roussy, Cancer Campus, Grand Paris
name: Chantal Kalifa, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01613391: Effect of Roux-en-Y Gastric Bypass Versus Laparoscopic Adjustable Gastric Band Operations on Resistin, Apelin and Visfatin Peptides
Official title: Effect of Roux-en-Y Gastric Bypass Versus Laparoscopic Adjustable Gastric Band Operations on Resistin, Apelin and Visfatin Peptides
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Morbid Obesity
Keywords: Visfatin
Resistin
Apelin
roux-en-y gastric bypass
laparoscopic adjustable gastric banding
morbid obesity
Lead sponsor: Istanbul University
Sponsor class: OTHER
First posted: 2012-06-07
Enrollment: 30
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Morbidly obese 15 patients underwent LAGB and 15 patients underwent RYGBP

Brief summary: This study aimed to measure, compare apelin, resistin, visfatin levels in patients underwent to RYGBP, LAGB and their relation with obesity.


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of morbid obesity
* Being underwent LAGB or RYGBP

Exclusion Criteria:

* Having prior abdominal surgery history

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Istanbul University Cerrahpasa Medical Faculty
Study officials:
References:
Clinical trial NCT03240991: Study of Clinical, Biological Characteristics and Quality of Life of Patients With Hereditary or Acquired Non Drug-induced Bradykinin-mediated Angioedema, Monitored in Besançon's Partner Site Reference Center for Studies of Kinin-mediated Angioedema (CREAK)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Angioedema
Keywords: bradykinin-mediated angiodema
quality of life
Lead sponsor: Centre Hospitalier Universitaire de Besancon
Sponsor class: OTHER
First posted: 2017-08-07
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Hereditary or Acquired non drug-induced bradykinin-mediated angioedema patients

Brief summary: This study aims to describe quality of life in hereditary or acquired non drug-related bradykinin-mediated angioedema patients, using validated questionnaires


Eligibility criteria: Inclusion Criteria:

* Clinically documented angioedema due to C1 inhibitor deficiency, hereditary (type I et II) or acquired
* Clinically documented angioedema with normal C1 inhibitor activity (hereditary type III)

Exclusion Criteria:

* Acquired angioedema with normal C1 inhibitor activity (former "drug-induced")
* Minor subjects
* Vulnerable subjects (under guardianship/curatorship/tutorship)
* Pregnant women

Primary outcomes:
measure: Dermatology Life Quality Index (DLQI)
timeFrame: 6 months
measure: Angioedema Quality of Life (AE-QoL) Questionnaire
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Besançon
country: France
facility: CHU Besançon
Study officials:
References:
Clinical trial NCT06488391: The Impact of Respiratory Training of DIBH Radiotherapy for Breast Cancer
Official title: The Impact of Patients' Daily Independent Breathing Training on the Accuracy and Side Effects of Deep Inspiratory Breath-Hold Radiotherapy for Breast Cancer
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Breast Cancer
Lead sponsor: Zhejiang Hospital
Sponsor class: OTHER
First posted: 2024-07-05
Enrollment: 80
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Breast cancer DIBH (Deep Inspiration Breath Hold) radiotherapy represents a high-precision treatment approach that substantially minimizes radiation exposure to vital organs such as the heart, thus enhancing protection of the patient's heart, lungs, contralateral breast, and other normal tissues compared to conventional radiotherapy techniques. This method requires meticulous precision, necessitating that patients possess exceptional respiratory control, which is facilitated through specialized equipment. Without such control, patients may encounter issues like missed targets, significant setup errors, and extended treatment durations.

In this study, the research team employed portable devices to enable patients to independently perform daily respiratory training exercises. The control group received no such devices; instead, these patients were merely instructed verbally on the importance of improving their breath-holding capabilities. The effectiveness of this intervention was evaluated by comparing the daily setup errors between the two groups. Additionally, the intervention's influence on patient outcomes was assessed by monitoring the toxicity and side effects experienced by the patients.


Eligibility criteria: Inclusion Criteria:

* Breast Cancer Radiotherapy Patients
* A single breath-hold can last for more than 10 seconds

Exclusion Criteria:

* A single breath-hold can last for more than 10 seconds

Primary outcomes:
measure: The daily measured setup error values of the image-guided radiotherapy device during the patient's treatment process.
timeFrame: 5 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: Zhejiang Hospital
state: Zhejiang
Study officials:
References:
Clinical trial NCT00348491: Efficacy of Lumiracoxib in Relieving Moderate to Severe Post-dental Surgery Pain, Compared to Both Placebo and Celecoxib
Official title: A Randomized, Double-blind, Double-dummy, Parallel Group, Single-center Study Evaluating the Analgesic Effect of Single Doses of Lumiracoxib 400 mg, Celecoxib 400 mg and Placebo in the Treatment of Post-dental Surgery Pain
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Pain
Keywords: Dental surgery
acute pain
lumiracoxib
celecoxib
Moderate to severe pain following dental surgery
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2006-07-04
Enrollment: 364
Sex: ALL
Minimum age (years): 17
Standard ages: CHILD
ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will assess the safety and efficacy of lumiracoxib 400 mg in relieving moderate to severe post-dental surgery pain, compared to both placebo and celecoxib 400 mg.


Eligibility criteria: Inclusion Criteria:

* Requiring extraction of two or more partially impacted or fully bony impacted third molars. At least one of the extractions must be mandibular
* Moderate to severe post-dental surgery pain intensity (as rated by the patient on the categorical pain intensity scale within five hours of surgery

Exclusion Criteria:

* Evidence or history of any cardiac and cerebral thrombotic/ ischemic diseases and/ or events

Other protocol-defined inclusion/exclusion criteria may apply

Primary outcomes:
measure: Superiority of a single dose of lumiracoxib 400 mg compared to placebo and celecoxib 400 mg based on a Summed (time weighted) Pain Intensity Difference calculated over 0-8 hours post-dose (SPID-8)
Secondary outcomes:
measure: Evaluate efficacy of a single dose of lumiracoxib 400 mg compared to placebo and to celecoxib 400 mg in relieving post dental surgery pain with respect to the following secondary efficacy variables:
measure: Time-specific Pain intensity Difference (PID) based on the categorical scale, Pain Relief (PR) based on the categorical scale, and Pain Relief Intensity Difference (PRID) (sum of PID and PR based on categorical scales) at time-points up to 24 hours after
measure: Time-specific PID based on VAS at time-points up to 24 hours after dosing
Other outcomes:
Locations:
city: Austin
country: United States
facility: Dental Research Clinic
state: Texas
Study officials:
affiliation: Novartis
name: Novartis Pharmaceuticals
role: STUDY_DIRECTOR
References:
citation: Fricke J, Davis N, Yu V, Krammer G. Lumiracoxib 400 mg compared with celecoxib 400 mg and placebo for treating pain following dental surgery: a randomized, controlled trial. J Pain. 2008 Jan;9(1):20-7. doi: 10.1016/j.jpain.2007.08.004. Epub 2007 Oct 15.
Clinical trial NCT02689791: Effect of Resistant Wheat Starch on Subjective Appetite and Food Intake in Healthy Adults
Official title: Effect of Resistant Wheat Starch on Subjective Appetite and Food Intake in Healthy Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Feeding Behavior
Keywords: Appetite
Food Intake
Satiety Hormones
Lead sponsor: Iowa State University
Sponsor class: OTHER
First posted: 2016-02-24
Enrollment: 31
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER

Brief summary: A randomized, single-blind, cross-over study was conducted to determine the effect of replacing standard wheat flour (SWF) with resistant wheat starch (RWS) on markers of appetite and food intake in healthy adults.


Eligibility criteria: Inclusion Criteria:

* BMI 18.5-29.9 kg/m2
* Regular breakfast consumers (\>5 days/week)

Exclusion Criteria:

* not weight stable (?3 kg weight change in previous 3 months)
* use/used tobacco products
* presence of acute or chronic illness
* restrained eater (\>13 on the restraint section of the three-factor eating questionnaire)

Primary outcomes:
measure: Caloric intake
timeFrame: Single Day
Secondary outcomes:
measure: Visual analogue scale measures of subjective appetite
timeFrame: Single Day
measure: Serum concentrations of biomarkers of appetite
timeFrame: 150 minutes
measure: Plasma concentrations of biomarkers of glycemic response
timeFrame: 150 minutes
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00993291: Deep Brain Stimulation (DBS) Frequency Effects on Gait in Parkinson's Disease(PD)
Official title: Effect of Frequency Change in Bilateral Subthalamic Nucleus (STN)-DBS on Gait Function in PD
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Parkinson Disease
Keywords: Parkinson's Disease
DBS
Frequency
Deep brain stimulation
Lead sponsor: Vanderbilt University
Sponsor class: OTHER
First posted: 2009-10-12
Enrollment: 20
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: In this study the investigators will evaluate the effect of both low and high frequency Deep Brain stimulation of the subthalamic nucleus (STN) in Parkinson's patients who have noted a change in their walking. The investigators' hypothesis is:

1. Stimulation at 60 Hertz (Hz) is associated with improved gait with increased stride length and faster time on the Stand walk sit test.
2. There is no worsening of the Unified Parkinson's Disease Rating Scale (UPDRS) at 60 Hz.


Eligibility criteria: Inclusion Criteria:

* Be a patient at the Vanderbilt Movement Disorders clinic.
* Report a change in their gait.
* Be able to walk independently when off PD medications for 12-16 hours.
* Have a stable dose of PD medications for the prior three months .
* Not cognitively impaired, so as to give informed consent.
* MMSE \> 24.

Exclusion Criteria:

* See inclusion criteria.

Primary outcomes:
measure: Change in Stride Length From Baseline
timeFrame: 1 hour
Secondary outcomes:
measure: Gait Velocity
timeFrame: 5 hours
measure: Time to Walk 14 Meters
timeFrame: 5 hours
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Vanderbilt University
state: Tennessee
Study officials:
affiliation: Vanderbilt Univeristy
name: Fenna T Phibbs, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01972191: Comparison of Three Corneal Horizontal Marking Techniques Using iTrace™
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Corneal Horizontal Marking.
Keywords: Toric marking, Corneal horizontal marking
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2013-10-30
Enrollment: 156
Sex: ALL
Minimum age (years): 50
Maximum age (years): 86
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Who visited professor Tae Im Kim's clinic, department of ophthalmology, Severance hospital.

Brief summary: Before astigmatism reducing surgery, accurate corneal horizontal marking before surgery is important. Due to new corneal topographic method, iTrace™ surgical workstation, precise evaluation of corneal horizontal marking is available. In this study the investigators compared three known corneal horizontal making techniques and evaluate accuracy of each methods using iTrace™.


Eligibility criteria: Inclusion Criteria:

* Patients who were scheduled to have cataract surgery
* Age between 50 to 85 years

Exclusion Criteria:

* With an underlying corneal or conjunctival disorder

Primary outcomes:
measure: The vertical height deviation and rotational axis misalignment amount of each three marking techniques, evaluated by iTrace surgical workstation.
timeFrame: Within 10 minutes after corneal horizontal marking.
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine
Study officials:
References:
citation: Hoffer KJ. Biometry of 7,500 cataractous eyes. Am J Ophthalmol. 1980 Sep;90(3):360-8. doi: 10.1016/s0002-9394(14)74917-7. No abstract available.
citation: Cha D, Kang SY, Kim SH, Song JS, Kim HM. New axis-marking method for a toric intraocular lens: mapping method. J Refract Surg. 2011 May;27(5):375-9. doi: 10.3928/1081597X-20101005-01. Epub 2010 Oct 15.